scispace - formally typeset
W

Waldemar Priebe

Researcher at University of Texas MD Anderson Cancer Center

Publications -  245
Citations -  10108

Waldemar Priebe is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Doxorubicin & Apoptosis. The author has an hindex of 53, co-authored 232 publications receiving 9102 citations. Previous affiliations of Waldemar Priebe include University of Texas System & University of Texas at Austin.

Papers
More filters
Journal ArticleDOI

Glioma cancer stem cells induce immunosuppressive macrophages/microglia

TL;DR: The gCSCs modulate innate immunity in glioblastoma by inducing immunosuppressive MΦs/microglia, and this capacity can be reversed by inhibiting phosphorylated STAT3.
Journal ArticleDOI

2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo

TL;DR: Treatment of tumors with both the glycolytic inhibitor 2-DG and ADR or paclitaxel results in a significant reduction in tumor growth compared with either agent alone, providing a rationale for initiating clinical trials using glyCOlytic inhibitors in combination with chemotherapeutic agents to increase their therapeutic effectiveness.
Journal ArticleDOI

A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.

TL;DR: WP1066, a novel inhibitor structurally related to AG490 but significantly more potent and active, is tested against human malignant glioma U87-MG and U373-MG cells in vitro and in vivo and concludes that WP1066 holds promise as a therapeutic agent against malignantgliomas.
Journal ArticleDOI

A Novel Small Molecule Inhibitor of Signal Transducers and Activators of Transcription 3 Reverses Immune Tolerance in Malignant Glioma Patients

TL;DR: A novel small molecule inhibitor of STAT3 that can penetrate the central nervous system (CNS) in mice and in physiologically relevant doses in vitro and reverse tolerance in immune cells isolated from glioblastoma multiforme (GBM) patients is described.